In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Time Dilation

Executive Summary

The faster we appear to be moving in discovery, it seems, the more pronounced the gap between technology advances and product commercialization. When we get back to earth-bound reality, new products aren't getting to the market any faster than they used to, and the speed of physician adoption appears to be a constant. The idea plays out in drug development, where we have to take the time to study the effect of a drug candidate in man before we can determine what clinical questions researchers should ask, much less what the answers are. It will also play out in personalized medicine: We're still not to the point where the first SNP panel has made its way into a pivotal trial, much less to regulatory agencies, physicians, or patient/consumers. That means the debate about the social or ethical ramifications of collecting and using pharmacogenomic information, and an understanding of the basis for the forces that will push against rapid adoption are premature. In a manner of speaking, we haven't even gotten to the stage of testing our responses in patieants.

You may also be interested in...

Coronavirus Update: Novartis Joins Vaccine Efforts With Gene Therapy Approach

Having kept out of the race to develop a vaccine, Novartis has joined efforts with a collaboration using the AAV gene therapy vector.

Philips Augments HealthSuite With New Clinical Trials Offering

Philips has added a Clinical Trials Accelerator functionality to the cloud-based HealthSuite digital platform, underlining its role in securely managing and collecting device and personal data for use by third-party clients seeking to build health care solutions.

Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer

Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts